Clinical trials recruiting in Derby, Connecticut

Phase breakdown

Conditions recruiting in Derby, Connecticut

Recruiting trials in Derby, Connecticut

• A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
  NCT07062965 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
  NCT06058377 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
  NCT06616584 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
  NCT05806515 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male
• Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
  NCT05174169 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
  NCT05642572 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
  NCT04239573 · Phase: Not specified · Ages: 50 Years to 75 Years · Sex: All (male and female)
• De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
  NCT04852887 · Phase: Phase 3 · Ages: 50 Years to 70 Years · Sex: All (male and female)
• Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
  NCT05879926 · Phase: Phase 3 · Ages: 18 Years to 60 Years · Sex: Female
• Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
  NCT03851445 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
  NCT04181060 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer
  NCT06551116 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
  NCT03723928 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
  NCT06876714 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
  NCT05929768 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
  NCT06116682 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
  NCT06031688 · Phase: Phase 2 · Ages: 18 Minutes and older · Sex: All (male and female)
• Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
  NCT06958328 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
  NCT04267848 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
  NCT05040360 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
  NCT06377852 · Phase: Phase 3 · Ages: 60 Years and older · Sex: All (male and female)
• Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
  NCT06769126 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)

Common questions

How many clinical trials are recruiting in Derby, Connecticut?

22 recruiting trials have at least one study site in Derby, Connecticut.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.